|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1246-1255.
Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-05-2041.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Mechanistic role of heat shock protein 70 in Bcr-Abl–mediated resistance to apoptosis in human acute leukemia cells
Fei Guo,
Celia Sigua,
Purva Bali,
Prince George,
Warren Fiskus,
Anna Scuto,
Srinivas Annavarapu,
Abdelmoughite Mouttaki,
Gautam Sondarva,
Sheng Wei,
Jie Wu,
Julie Djeu, and
Kapil Bhalla
From the Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
Bcr-Abl–expressing primary or cultured leukemia cells display high levels of the antiapoptotic heat shock protein (hsp) 70 and are resistant to cytarabine (Ara-C), etoposide, or Apo-2L/TRAIL (TNF-related apoptosis-inducing ligand)–induced apoptosis. Conversely, a stable expression of the cDNA of hsp70 in the reverse orientation attenuated not only hsp70 but also signal transducers and activators of transcription 5 (STAT5) and Bcl-xL levels. This increased apoptosis induced by cytarabine, etoposide, or Apo-2L/TRAIL. Ectopic expression of hsp70 in HL-60 cells (HL-60/hsp70) inhibited Ara-C and etoposide-induced Bax conformation change and translocation to the mitochondria; attenuated the accumulation of cytochrome c, Smac, and Omi/HtrA2 in the cytosol; and inhibited the processing and activity of caspase-9 and caspase-3. Hsp70 was bound to death receptors 4 and 5 (DR4 and DR5) and inhibited Apo-2L/TRAIL-induced assembly and activity of the death-inducing signaling complex (DISC). HL-60/hsp70 cells exhibited increased levels and DNA binding activity of STAT5, which was associated with high levels of Pim-2 and Bcl-xL and resistance to apoptosis. Expression of the dominant negative (DN) STAT5 resensitized HL-60/hsp70 cells to cytarabine, etoposide, and Apo-2L/TRAIL–induced apoptosis. Collectively, these findings suggest that hsp70 inhibits apoptosis upstream and downstream of the mitochondria and is a promising therapeutic target for reversing drug-resistance in chronic myeloid leukemia-blast crisis and acute myeloid leukemia cells. (Blood. 2005;105:1246-1255)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Is hsp70 another target for Ph+ leukemias?
- Gert Ossenkoppele
Blood 2005 105: 917.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. Yoshida, Y. Zhang, L. A. Rivera Rosado, and B. Zhang
Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells
Mol. Cancer Res.,
November 1, 2009;
7(11):
1835 - 1844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Dudeja, S M Vickers, and A K Saluja
The role of heat shock proteins in gastrointestinal diseases
Gut,
July 1, 2009;
58(7):
1000 - 1009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bots and R. W. Johnstone
Rational Combinations Using HDAC Inhibitors
Clin. Cancer Res.,
June 15, 2009;
15(12):
3970 - 3977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Brierley-Hobson
Binding of (-)-epigallocatechin-3-gallate to the Hsp70 ATPase domain may promote apoptosis in colorectal cancer
Bioscience Horizons,
March 1, 2008;
1(1):
9 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Hostetter, C. R. K. Loeb, F. Chu, and C. S. Craik
Hip Is a Pro-survival Substrate of Granzyme B
J. Biol. Chem.,
September 21, 2007;
282(38):
27865 - 27874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lee, J. H. Bae, M. J. Kim, H. S. Lee, M. K. Lee, B. S. Chung, D. W. Kim, C. D. Kang, and S. H. Kim
Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
1084 - 1092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dasmahapatra, N. Yerram, Y. Dai, P. Dent, and S. Grant
Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Clin. Cancer Res.,
July 15, 2007;
13(14):
4280 - 4290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Blood,
July 15, 2007;
110(2):
678 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-C. Kuo, C.-M. Liang, C.-Y. Lai, and S.-M. Liang
Involvement of Heat Shock Protein (Hsp)90beta but Not Hsp90{alpha} in Antiapoptotic Effect of CpG-B Oligodeoxynucleotide
J. Immunol.,
May 15, 2007;
178(10):
6100 - 6108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wetzler, J. C. Earp, M. T. Brady, M. K. Keng, and W. J. Jusko
Synergism between Arsenic Trioxide and Heat Shock Protein 90 Inhibitors on Signal Transducer and Activator of Transcription Protein 3 Activity--Pharmacodynamic Drug-Drug Interaction Modeling
Clin. Cancer Res.,
April 1, 2007;
13(7):
2261 - 2270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-C. Kuo, S.-M. Liang, and C.-M. Liang
CpG-B Oligodeoxynucleotide Promotes Cell Survival via Up-regulation of Hsp70 to Increase Bcl-xL and to Decrease Apoptosis-inducing Factor Translocation
J. Biol. Chem.,
December 15, 2006;
281(50):
38200 - 38207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Gyurkocza, J. Plescia, C. M. Raskett, D. S. Garlick, P. A. Lowry, B. Z. Carter, M. Andreeff, M. Meli, G. Colombo, and D. C. Altieri
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
J Natl Cancer Inst,
August 2, 2006;
98(15):
1068 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al.
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
Cancer Res.,
November 15, 2005;
65(22):
10536 - 10544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
